Pregled bibliografske jedinice broj: 1251681
Chemobrachyradiotherapy and consolidation chemotherapy in treatment of locally advanced cervical cancer
Chemobrachyradiotherapy and consolidation chemotherapy in treatment of locally advanced cervical cancer // Wiener klinische Wochenschrift, 133 (2021), 21-22; 1155-1161 doi:10.1007/s00508-021-01958-0 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1251681 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Chemobrachyradiotherapy and consolidation
chemotherapy in treatment of locally advanced
cervical cancer
Autori
Tomić, Krešimir ; Berić Jozić, Gordana ; Parić, Ana ; Marijanović, Inga ; Lasić, Ivan ; Soldo, Dragan ; Vrdoljak, Eduard
Izvornik
Wiener klinische Wochenschrift (0043-5325) 133
(2021), 21-22;
1155-1161
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Squamous cell carcinoma ; Chemoradiotherapy ; Radiotherapy ; Brachytherapy ; Adjuvant chemotherapy
Sažetak
Background: Given the lack of primary and secondary prevention programs and cancer awareness in general, cervical cancer remains one of the main causes of cancer-related death in developing countries, such as Bosnia and Herzegovina. Optimization of combinations of external radiation therapy (ERT), brachytherapy and chemotherapy is still needed to improve outcomes in the treatment of advanced cervical cancer. Patients and methods: We retrospectively analyzed 48 consecutive patients with Federation Internationale de Gynecologie et d'Obstetrique (FIGO) 2009 stage IB2-IVA, who were treated with primary concomitant chemobrachyradiotherapy (CCBRT) and consolidation chemotherapy at the Department of Oncology, University Hospital Mostar, Bosnia and Herzegovina between December 2012 and June 2020. Patients were treated with ERT plus two cycles of concomitant chemobrachytherapy with ifosfamide and cisplatin and low-dose rate (LDR) brachytherapy followed by four cycles of consolidation chemotherapy at 3- week intervals. We evaluated local control rate (LCR), disease-free survival (DFS), overall survival (OS), disease-specific survival (DSS) and toxicity. Results: After 45.5 months (interquartile range, IQR = 47 months) of median follow-up, 5-year DFS was 72.8% (95% confidence interval. CI 59-78%), OS was 76.6% (95% CI 60- 79%), and DSS was 88% (95% CI 71-86%) with acceptable toxicity. LCR was 94%. Conclusion: Primary CCBRT and consolidation chemotherapy applied in standard clinical practice in the treatment of locally advanced cervical cancer (LACC) produce respectable outcomes.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE